ABIVX ulcerative colitis drug trial update

What happened: On Tuesday, Abivax SA shares plummeted, losing up to 40% in Paris and New York. The clinical-stage drugmaker's stock crashed after it reported new data from its phase 2b trial of ABX464, an experimental drug for ulcerative colitis. The trial results showed a remission rate of about 40% for both doses tested, meeting its endpoints. However, the data also revealed cancer cases among patients, sparking investor concern.

Market impact: The biotech sector, particularly companies focused on inflammatory bowel disease treatments, was affected. The revelation of cancer cases in the trial raised safety concerns, leading to a sell-off in Abivax's shares. This development could influence investor sentiment towards other biotechs with similar drug profiles, potentially impacting their valuations.

What to watch next: Abivax's share price performance will be closely watched, with any further declines indicating sustained investor concern. Upcoming catalysts include the company's presentation of full trial data at a scientific conference, scheduled for later this year. Additionally, the U.S. Food and Drug Administration's (FDA) response to these safety findings will be crucial, as it could impact the drug's regulatory path and Abivax's future prospects.